Short answer
Esperion Therapeutics, Inc. (ESPR) filed an 8-K current report with the SEC on March 3, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure). Esperion acquiring Corstasis Therapeutics via cash merger for $75M upfront, closing deadline May 1, 2026.
Esperion Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Esperion acquiring Corstasis Therapeutics via cash merger for $75M upfront, closing deadline May 1, 2026
- Total deal value up to $255M including $180M in regulatory/commercial milestone payments plus royalties
- All-cash transaction; Corstasis shareholders, option holders, and RSU holders receive pro rata cash payouts
- Corstasis becomes wholly-owned subsidiary; deal structured with escrow/expense accounts subject to post-closing purchase price adjustment
- Strategic bet on Corstasis pipeline: milestone triggers tied to regulatory approvals and future product sales signal potential new revenue streams for ESPR
Item 7.01 · Regulation FD Disclosure
- Esperion (ESPR) entering merger with Corstasis: deal announced March 3, 2026
- Investor call held 8:00 a.m. ET March 3 to discuss transaction terms and strategic rationale
- Full deal details in Exhibit 99.1 (press release) and Exhibit 99.2 (supplemental presentation)
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Esperion Therapeutics, Inc. 8-K filings
Get the next ESPR 8-K as it lands
Follow ESPR for push alerts, or ask the research agent what this filing means.